Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea flag South Korea · Delayed Price · Currency is KRW
111,300
+2,400 (2.20%)
Last updated: Sep 17, 2026, 3:00 PM KST

Daewoong Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,635,2151,570,8911,422,6831,375,3291,280,0921,152,976
Revenue Growth
9.87%10.42%3.44%7.44%11.03%9.24%
Gross Profit
854,636822,532734,168687,108638,095543,749
Operating Income
189,232195,508145,238121,11895,79788,729
Net Income
195,473195,85624,735121,73942,24024,506
Earnings Per Share
16988.6417021.642149.6510655.613815.952226.87
EPS Growth
160.30%691.83%-79.83%179.24%71.36%86.18%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Pharmaceutical Manufacturing and Sales
1,656,6231,600,7691,458,0901,409,5201,316,6011,184,293
Service Provision
38,63540,46438,39723,6489,8427,797
Other
3,1303,0277,1938,2625,2321,465
Consolidation
-63,173-73,369-80,996-66,100-51,583-40,580
Total
1,635,2151,570,8911,422,6831,375,3291,280,0921,152,976

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
158,418172,801116,347137,685140,651173,734
Total Debt
925,017829,390649,249441,270446,711445,695
Net Cash (Debt)
-766,599-656,589-532,902-303,585-306,060-271,961
Net Cash Growth
------
Net Cash Per Share
-66625.54-57063.54-46314.03-26572.35-27649.69-24713.54

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
162,145149,20551,492136,009118,21539,994
Capital Expenditures
-266,095-191,534-155,145-109,338-65,227-29,088
Free Cash Flow
-103,949-42,329-103,65326,67152,98810,906
Free Cash Flow Growth
----49.67%385.84%-85.36%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
52.26%52.36%51.60%49.96%49.85%47.16%
Operating Margin
11.57%12.45%10.21%8.81%7.48%7.70%
Pretax Margin
10.98%12.21%3.97%8.87%2.99%1.71%
Profit Margin
11.95%12.47%1.74%8.85%3.30%2.13%
FCF Margin
-6.36%-2.70%-7.29%1.94%4.14%0.95%

Dividends

Fiscal YearCurrentFY 2025
Period EndingSep '26 Dec '25
Dividend Per Share
600.000600.000
Dividend Per Share Growth
0%-
Dividend Yield
0.54%0.35%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
6.5510.1258.8011.0441.5466.85
Forward PE
7.7811.7614.3914.7722.7741.35
P/FCF Ratio
---50.3933.11150.21
PS Ratio
0.781.261.020.981.371.42